enGene Therapeutics Inc.
ENGN
$1.70
$0.010.59%
NASDAQ
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -126.85M | -122.44M | -117.30M | -94.72M | -79.88M |
| Total Depreciation and Amortization | 670.00K | 596.00K | 509.00K | 421.00K | 373.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.13M | 9.59M | 7.81M | 6.87M | 6.45M |
| Change in Net Operating Assets | 4.06M | 9.80M | 9.74M | -6.42M | -2.34M |
| Cash from Operations | -110.00M | -102.45M | -99.24M | -93.85M | -75.39M |
| Capital Expenditure | -1.39M | -1.34M | -1.49M | -1.29M | -584.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.39M | -65.13M | -23.65M | -189.62M | -191.70M |
| Cash from Investing | -60.78M | -66.47M | -25.14M | -190.90M | -192.29M |
| Total Debt Issued | 25.00M | 25.00M | -- | 0.00 | 0.00 |
| Total Debt Repaid | -23.75M | -23.75M | -699.00K | -699.00K | 0.00 |
| Issuance of Common Stock | 151.80M | 152.00M | 2.22M | 60.39M | 60.41M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.99M | -10.06M | -- | 0.00 | 0.00 |
| Cash from Financing | 143.06M | 143.18M | 1.52M | 59.69M | 60.41M |
| Foreign Exchange rate Adjustments | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.72M | -25.73M | -122.85M | -225.06M | -207.27M |